File(s) under permanent embargo

Reason: This item is currently closed access.

Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)

journal contribution
posted on 11.04.2019, 09:15 by P Khoury, P Akuthota, SJ Ackerman, JR Arron, BS Bochner, MH Collins, J-E Kahn, PC Fulkerson, GJ Gleich, R Gopal-Srivastava, EA Jacobsen, KM Leiferman, L-S Francesca, SK Mathur, M Minnicozzi, C Prussin, ME Rothenberg, F Roufosse, K Sable, D Simon, H-U Simon, LA Spencer, J Steinfeld, AJ Wardlaw, ME Wechsler, PF Weller, AD Klion
Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.

Funding

NIH. Grant Numbers: K08 HL116429, UG1 HL139117 FDA. Grant Number: R01FD004086 APFED. Grant Numbers: R01 AI072265, P01 HL107151, R01 AI105839 Campaign Urging Research for Eosinophilic Disease Buckeye Foundation Sunshine Charitable Foundation Rare Disease Clinical Research Network National Fund for Scientific Research. Grant Number: F 5/4/150/4 Israel Science Foundation. Grant Number: ISF 472/15 National Institute for Health Research NIAID. Grant Number: R37020241

History

Citation

J Leukoc Biol, 2018, 104 (1), pp. 69-83

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation

Version

AM (Accepted Manuscript)

Published in

J Leukoc Biol

Publisher

Society for Leukocyte Biology

eissn

1938-3673

Acceptance date

21/02/2018

Copyright date

2018

Publisher version

https://jlb.onlinelibrary.wiley.com/doi/full/10.1002/JLB.5MR0118-028R

Notes

The file associated with this record is under a permanent embargo in accordance with the publisher's policy. The full text may be available through the publisher links provided above.

Language

en